Glaucoma, an eye disease which affects nearly 70 million people worldwide, may be an autoimmune disease, suggests a new research.
In a study of mice, the researchers showed that the body's own T cells are responsible for the progressive retinal degeneration seen in glaucoma.
Furthermore, these T cells appear to be primed to attack retinal neurons as the result of previous interactions with bacteria that normally live in our body, said the study published in the journal Nature Communications.
The discovery suggests that it was possible to develop new treatments for glaucoma by blocking this autoimmune activity.
"This opens a new approach to prevent and treat glaucoma," said study co-author Jianzhu Chen, Professor of Biology at Massachusetts Institute of Technology (MIT).
Glaucoma is a group of related eye disorders that cause damage to the optic nerve that carries information from the eye to the brain.
One of the biggest risk factors for glaucoma is elevated pressure in the eye, which often occurs as people age, and the ducts that allow fluid to drain from the eye become blocked.
The disease often goes undetected at first and patients may not realise they have the disease until half of their retinal ganglion cells have been lost.
Most treatments focus on lowering pressure in the eye (also known as intraocular pressure).
However, in many patients, the disease worsens even after intraocular pressure returns to normal.
In studies in mice, the researchers found the same effect.
"That led us to the thought that this pressure change must be triggering something progressive, and the first thing that came to mind is that it has to be an immune response," study co-author Dong Feng Chen, Associate Professor at Harvard Medical School, said.
Further studies revealed that the glaucoma-linked T cells target proteins called heat shock proteins, which help cells respond to stress or injury.
In human patients with glaucoma, the researchers found that they had five times the normal level of T cells specific to heat shock proteins.
--IANS
asj/gb/sed
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
